NASDAQ · BCDA
BioCardia, Inc.
$0.93-$0.02 (-2.26%)
BioCardia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.56% below the high.
Loading market information…
NASDAQ · CELZ · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Creative Medical Technology Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Creative Medical Technology Holdings, Inc.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of -$0.24. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Creative Medical Technology Holdings, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $3.00K |
| Q4 2024 | Mar 14, 2025 | -$1.12-77.78% vs estimate | $3.00K |
|---|
| Q3 2024 | Nov 8, 2024 | -$0.75+11.76% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.93-$0.02 (-2.26%)
BioCardia, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.56% below the high.
$5.05+$1.34 (+36.12%)
Adial Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.41% below the high.
$0.86-$0.05 (-5.91%)
Phio Pharmaceuticals Corp.’s quoted price sits in the lower half of its reported 52-week range, 79.41% below the high.
$1.76-$0.60 (-25.42%)
Kiora Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.52% below the high.
$0.49-$0.04 (-8.22%)
Aprea Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.87% below the high.
$1.07$0.00 (0.0%)
Acurx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.81% below the high.
$1.22+$0.03 (+2.52%)
Alzamend Neuro Inc’s quoted price sits in the lower half of its reported 52-week range, 54.48% below the high.
$1.75+$0.05 (+2.94%)
Cardio Diagnostics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.88% below the high.
